Home > Qtrly Results > GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS
Quarterly Results Analysis [Sep2026]

GLENMARK PHARMACEUTICALS is part of below Screeners ↓
Best 1M Momentum Mid Cap Stocks
COMMUNITY POLL
for GLENMARK PHARMACEUTICALS
Please provide your vote to see the results

GLENMARK PHARMACEUTICALS Quarterly Results

Consolidated Sep2026
UnAudited
Jun2026
UnAudited
Mar2026
UnAudited
Dec2025
UnAudited
Sep2025
UnAudited
Jun2025
UnAudited
Mar2025
UnAudited
Dec2024
UnAudited
Revenues ₹4,247 Cr ₹4,018 Cr ₹3,771 Cr ₹3,901 Cr ₹6,047 Cr ₹3,264 Cr ₹3,256 Cr ₹3,388 Cr
Expenses ₹3,384 Cr ₹3,214 Cr ₹3,008 Cr ₹3,031 Cr ₹3,687 Cr ₹2,684 Cr ₹2,695 Cr ₹2,787 Cr
Operating Income ₹864 Cr ₹805 Cr ₹763 Cr ₹870 Cr ₹2,360 Cr ₹581 Cr ₹561 Cr ₹600 Cr
Other Income ₹3 Cr ₹66 Cr ₹189 Cr ₹44 Cr ₹201 Cr ₹26 Cr ₹12 Cr ₹31 Cr
Interest ₹64 Cr ₹54 Cr ₹43 Cr ₹41 Cr ₹66 Cr ₹58 Cr ₹67 Cr ₹52 Cr
Depreciation ₹180 Cr ₹173 Cr ₹148 Cr ₹154 Cr ₹141 Cr ₹130 Cr ₹125 Cr ₹123 Cr
Profit Before Tax ₹338 Cr ₹643 Cr ₹388 Cr ₹534 Cr ₹967 Cr ₹96 Cr ₹8 Cr ₹456 Cr
Profit After Tax ₹264 Cr ₹483 Cr ₹301 Cr ₹403 Cr ₹610 Cr ₹47 Cr ₹4 Cr ₹348 Cr
EPS ₹9.35 ₹17.11 ₹10.68 ₹14.29 ₹21.63 ₹1.66 ₹0.16 ₹12.33
Industry Peers & Returns1W1M1Y
GLENMARK PHARMACEUTICALS 7.1% 17% 40.5%
SUN PHARMACEUTICAL INDUSTRIES 7.3% 8.4% 13.1%
DIVIS LABORATORIES 15.3% 24.1% 63%
TORRENT PHARMACEUTICALS 1% 2.5% 33.4%
CIPLA 0.4% 7.9% -6.2%
DR REDDYS LABORATORIES 1% 15.9% 14%
MANKIND PHARMA 5.1% 12.3% 8.8%
LUPIN -0.2% 2.7% -0.2%
ZYDUS LIFESCIENCES 1.9% 8.8% 23.4%

GLENMARK PHARMACEUTICALS Quarterly Revenues

Revenues
Q-o-Q

5.69 %

Y-o-Y

-29.76 %

Quarters Revenues % Change
Sep2026 ₹4,247 Cr
5.69
Jun2026 ₹4,018 Cr
6.57
Mar2026 ₹3,771 Cr
-3.33
Dec2025 ₹3,901 Cr
-35.49
Sep2025 ₹6,047 Cr
85.23
Jun2025 ₹3,264 Cr
0.25
Mar2025 ₹3,256 Cr
-3.88
Dec2024 ₹3,388 Cr -

GLENMARK PHARMACEUTICALS Quarterly Operating Profit

Operating Profit
Q-o-Q

7.33 %

Y-o-Y

-63.39 %

Quarters Operating Profit % Change
Sep2026 ₹864 Cr
7.33
Jun2026 ₹805 Cr
5.53
Mar2026 ₹763 Cr
-12.32
Dec2025 ₹870 Cr
-63.14
Sep2025 ₹2,360 Cr
306.45
Jun2025 ₹581 Cr
3.47
Mar2025 ₹561 Cr
-6.53
Dec2024 ₹600 Cr -
Operating Margins
Q-o-Q

1.55 %

Y-o-Y

-47.87 %

Quarters Operating Margin% % Change
Sep2026 20.34%
1.55
Jun2026 20.03%
-0.94
Mar2026 20.22%
-9.33
Dec2025 22.3%
-42.85
Sep2025 39.02%
119.46
Jun2025 17.78%
3.19
Mar2025 17.23%
-2.77
Dec2024 17.72% -

GLENMARK PHARMACEUTICALS Quarterly Profit After Tax

Profit After Tax(PAT)
Q-o-Q

-45.36 %

Y-o-Y

-56.78 %

Quarters Profit After Tax % Change
Sep2026 ₹264 Cr
-45.36
Jun2026 ₹483 Cr
60.24
Mar2026 ₹301 Cr
-25.27
Dec2025 ₹403 Cr
-33.94
Sep2025 ₹610 Cr
1,199.54
Jun2025 ₹47 Cr
971.46
Mar2025 ₹4 Cr
-98.74
Dec2024 ₹348 Cr -
PAT Margins
Q-o-Q

-48.34 %

Y-o-Y

-38.51 %

Quarters PAT Margin(%) % Change
Sep2026 6.21 %
-48.34
Jun2026 12.02 %
50.44
Mar2026 7.99 %
-22.73
Dec2025 10.34 %
2.38
Sep2025 10.1 %
601.39
Jun2025 1.44 %
1,007.69
Mar2025 0.13 %
-98.73
Dec2024 10.27 % -

GLENMARK PHARMACEUTICALS Quarterly Earnings Per Share (EPS)

EPS
Q-o-Q

-45.35 %

Y-o-Y

-56.77 %

Quarters EPS % Change
Sep2026 ₹9.35
-45.35
Jun2026 ₹17.11
60.21
Mar2026 ₹10.68
-25.26
Dec2025 ₹14.29
-33.93
Sep2025 ₹21.63
1,203.01
Jun2025 ₹1.66
937.50
Mar2025 ₹0.16
-98.70
Dec2024 ₹12.33 -

You may also like the below Video Courses